SBC Medical Group Holdings Inc., the leading Japanese owner and operator of aesthetic medical clinics, has announced a strategic partnership with BLEZ ASIA Co., Ltd. to expand into Thailand's growing aesthetic medicine market. This move represents a significant step in the company's broader Asian expansion strategy following its recent entry into Singapore.
The partnership addresses a critical gap in Thailand's aesthetic medicine landscape, which is currently fragmented with many small-scale operators providing inconsistent service quality. According to estimates compiled by SBC, demand for aesthetic medicine in Thailand is projected to reach nearly $1.2 billion by 2033, growing at a compound annual growth rate of 13.5% between now and then. The market's rapid expansion, combined with Thailand's substantial Japanese expatriate population of approximately 60,000 people who have limited access to Japanese-quality aesthetic treatments, creates substantial opportunity for SBC's entry.
Under the e-consulting agreement, SBC will provide management support to a new clinic BLEZ ASIA is preparing to open in Bangkok's Asok district, focused primarily on dermatological treatments such as pigmentation and spot removal. SBC will advise on developing clinical protocols aligned with its quality standards and assist in selecting medical devices and treatment methods optimized for local skin characteristics and environmental conditions. The clinic is expected to commence operations by year-end.
BLEZ ASIA operates more than twenty pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. This partnership builds on SBC's successful expansion into Singapore through a partnership with Aesthetic Healthcare Holdings in late 2024, accelerating the company's regional growth strategy. Beginning with the Japanese expatriate community, SBC aims to steadily build its business with the goal of providing consistently high-level medical services and establishing new value in the Thai aesthetic medicine market.
Japanese aesthetic medicine is globally competitive for its precision and high safety standards, qualities that SBC has built its reputation upon in Japan where it operates 258 locations and maintains a 72% return customer rate. The company recently overhauled its pricing structure to attract and retain customers, contributing to a 15% year-over-year growth in annual patient visits during the third quarter.
Yoshiyuki Aikawa, CEO of SBC, emphasized the strategic importance of this partnership, stating that partnering with a trusted local leader like BLEZ in this fast-growing Thai market represents a significant step forward in the company's Asia strategy. The collaboration aims to create a model where Japan's advanced medical services can take root locally and deliver new value to Thai consumers.
Market trends in both Japan and Thailand show consumers seeking high-quality aesthetic treatments at affordable prices, with preferences for subtle, natural-looking enhancements that require minimal downtime. Non-surgical procedures and hair removal are particularly popular among consumers looking for accessible aesthetic improvements. Naoki Iida, CEO of BLEZ ASIA, noted that the Thai aesthetic medicine market continues to grow rapidly with increasing focus on quality and safety, making the partnership with SBC an invaluable opportunity to establish Japanese-standard, high-quality medical services in Thailand.
